Eye treatments using synthetic thyroid hormone compositions
First Claim
Patent Images
1. A method of inhibiting hyaluronic acid secretion in cells in an eye comprising:
- topically applying an effective amount of a synthetic thyroid hormone to an eye, thereby inhibiting hyaluronic acid secretion by cells in the eye, wherein said synthetic thyroid hormone at a concentration of 10 micromolar or less inhibits at least 10% of total hyaluronic acid secretion from cultured human trabecular meshwork cells after three days culture at 37°
C. compared to human trabecular meshwork cells cultured in the absence of said synthetic thyroid hormone after three days of culture at 37°
C., and with the proviso that said non-systemically applying does not include topical application of T3 or T4 isolated from naturally occurring tissues.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention involves the discovery that synthetic thyroid hormones can be used as compositions to reduce intraocular pressure in vivo. Methods of screening synthetic thyroid hormones for effect on intraocular pressure, aqueous pressure, hydraulic conductivity, hyaluronic acid secretion, and extracellular matrix assembly are provided. Methods of treating glaucoma and treating excess intraocular pressure with synthetic thyroid hormones and compositions therefore are also provided.
31 Citations
21 Claims
-
1. A method of inhibiting hyaluronic acid secretion in cells in an eye comprising:
-
topically applying an effective amount of a synthetic thyroid hormone to an eye, thereby inhibiting hyaluronic acid secretion by cells in the eye, wherein said synthetic thyroid hormone at a concentration of 10 micromolar or less inhibits at least 10% of total hyaluronic acid secretion from cultured human trabecular meshwork cells after three days culture at 37°
C. compared to human trabecular meshwork cells cultured in the absence of said synthetic thyroid hormone after three days of culture at 37°
C., andwith the proviso that said non-systemically applying does not include topical application of T3 or T4 isolated from naturally occurring tissues. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)
-
Specification